Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
adverse drug reaction |
| gptkbp:alsoKnownAs |
heparin-induced thrombocytopenia type II
|
| gptkbp:causedBy |
gptkb:heparin
|
| gptkbp:characterizedBy |
thrombosis
thrombocytopenia |
| gptkbp:complication |
myocardial infarction
stroke venous thrombosis limb gangrene arterial thrombosis |
| gptkbp:diagnosedBy |
clinical criteria
laboratory testing for HIT antibodies |
| gptkbp:firstDescribed |
1970s
|
| https://www.w3.org/2000/01/rdf-schema#label |
Type II HIT
|
| gptkbp:ICD-10_code |
D75.82
|
| gptkbp:mechanismOfAction |
immune-mediated
antibodies against platelet factor 4-heparin complex |
| gptkbp:onsetAfterExposure |
5-10 days
|
| gptkbp:prevalence |
1-5% of patients exposed to heparin
|
| gptkbp:riskFactor |
gptkb:unfractionated_heparin
low molecular weight heparin |
| gptkbp:treatment |
alternative anticoagulation
discontinuation of heparin |
| gptkbp:bfsParent |
gptkb:heparin-induced_thrombocytopenia
|
| gptkbp:bfsLayer |
7
|